Skip to content

EstPharma OÜ

Registry code (registrikood) 14915921Private limited company (Osaühing)VAT EE102242135Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€5.3M
▲ 11.6% vs 2024
Profit before tax (2025)
-€263k
Employees, FTE (2025)
17
State taxes paid, last 4 quarters
€295k

Revenue, profit and employees, 2020–2025

€2.7M2020€3.0M2021€3.4M2022€4.4M2023€4.7M2024€5.3M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2020€2,668,745-€132,633-€132,625-€130,12517
2021€3,020,027€83,926€83,937-€46,18814
2022€3,378,784-€98,538-€98,527-€144,71517
2023€4,359,356-€143,446-€143,437-€288,15217
2024€4,733,689€80,670€80,676-€207,47617
2025€5,282,539-€263,134-€263,128-€470,60417

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2020€101,629€661,121€791,246—-€130,125
2021€56,041€475,904€522,092—-€46,188
2022€71,774€678,599€823,314—-€144,715
2023€65,929€740,510€1,028,662—-€288,152
2024€89,600€1,026,686€1,234,162—-€207,476
2025€90,105€739,853€1,210,457—-€470,604

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€52,883€43,461€820,53621
2022 Q2€50,954€40,859€799,01922
2022 Q3€52,182€49,478€790,95427
2022 Q4€69,725€63,542€1,069,04425
2023 Q1€68,433€63,009€1,151,55525
2023 Q2€69,618€63,290€1,184,11524
2023 Q3€77,608€71,459€1,107,07623
2023 Q4€77,783€68,966€1,193,16324
2024 Q1€78,291€67,715€1,293,96025
2024 Q2€73,727€67,303€1,194,74726
2024 Q3€82,547€74,177€1,089,70626
2024 Q4€80,307€70,299€1,307,84225
2025 Q1€136,029€76,523€1,606,84126
2025 Q2€69,173€67,734€1,269,72725
2025 Q3€85,211€74,029€1,413,53825
2025 Q4€81,747€68,317€1,463,74826
2026 Q1€77,236€68,171€1,551,69623
2026 Q2€68,450€66,582€1,658,88722
2026 Q3€67,411€61,236€1,647,26124

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), EstPharma OÜ reported revenue of €5,282,539.

The company recorded a net loss of €263,128 in the 2025 financial year.

Revenue increased by 11.6% from €4,733,689 in 2024 to €5,282,539 in 2025.

Revenue grew at a compound annual rate of 14.6% between 2020 and 2025.

Equity accounted for -63.6% of total assets of €739,853 at the end of the 2025 reporting period.

With 17 full-time-equivalent employees in 2025, revenue per employee was €310,738.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, EstPharma OÜ reported €6,321,592 in turnover.

EMTA recorded 24 employees for the quarter ending Q3 2026, compared with 17 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.